Precision BioLogic Enhances Market Position with George King Bio-Medical Acquisition

Precision BioLogic Acquires George King Bio-Medical

Precision BioLogic Inc., a prominent name in the development of hemostasis diagnostic products, has officially announced the acquisition of George King Bio-Medical, Inc. This strategic move is seen as a significant step towards enhancing both companies' impact within the bleeding disorders community. The announcement was made on October 16, 2025, highlighting a shared vision and commitment to improving lives through innovative diagnostic solutions.

The Legacy of George King Bio-Medical

Founded in 1973 by George J. King, George King Bio-Medical has forged a remarkable path over its 50-plus years of operation. Its mission has always centered around supporting individuals with bleeding disorders, bolstered by a keen understanding of their needs and challenges. The company is well-regarded for its quality offerings, including fresh frozen human plasmas that are crucial for clinical laboratories. This legacy is set to continue under the Precision BioLogic umbrella, with both companies focusing on their established customer base while exploring new avenues for growth.

Paul Empey, President and CEO of Precision BioLogic, emphasized the synergy between the two organizations. “Since its inception, George King Bio-Medical has remained steadfast in its mission—helping those affected by bleeding disorders,” he noted. Empey expressed optimism about the future collaboration, indicating that together they can enhance customer relationships and potentially expand their reach in the medical community.

The Vision for the Future

Kathryn Blasco, the CEO and President of George King Bio-Medical, shares this optimistic outlook. She noted that merging with Precision BioLogic represents an opportunity to expand their legacy of compassion and innovation. “The future looks promising for us and our customers,” she stated, reinforcing the shared commitment of both companies to better serve the community.

Despite this monumental change, both organizations will maintain their focus on regular operations and customer service. Their loyal clientele can expect continuity in support and product offerings as they transition into longer-term strategic initiatives under the guidance of Precision BioLogic.

Advancements in Hemostasis Diagnostics

Precision BioLogic has established itself as a leader in the market, known for its CRYOcheck™ line of products utilized by healthcare professionals worldwide to diagnose coagulation disorders. Since acquiring Affinity Biologicals in late 2018, the company's portfolio has expanded significantly, allowing for enhanced clinical and research capabilities in the field of hemostasis.

The integration of George King Bio-Medical into Precision BioLogic's framework heralds a significant enhancement in their combined capacity to offer innovative solutions for bleeding disorders. This acquisition not only aligns with the companies' goals of improving healthcare outcomes but also underscores a commitment to advancing knowledge and understanding of complex bleeding conditions.

Conclusion

As Precision BioLogic embarks on this new chapter with George King Bio-Medical, the hemostasis diagnostic sector watches closely. There is a palpable sense of excitement regarding the continued dedication to customer care through innovative products and services that meet the needs of those within the bleeding disorders community. Collectively, these organizations stand poised to lead transformative changes in medical diagnostics, directly influencing patient care positively long into the future.

For more information about Precision BioLogic and their latest offerings, you can visit their website at www.precisionbiologic.com. Similarly, insight into George King Bio-Medical's offerings can be found at www.kingbiomed.com.